- Home
- MDIA vs RNXT Comparison
MDIA vs RNXT Comparison
Compare MDIA & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDIA | RNXT |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.7M | 79.4M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDIA | RNXT |
|---|---|---|
| Price | $1.04 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.13 |
| AVG Volume (30 Days) | 7.7K | ★ 396.2K |
| Earning Date | 11-18-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $133,336,000.00 | $1,123,000.00 |
| Revenue This Year | N/A | $244.84 |
| Revenue Next Year | N/A | $195.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 39.52 | ★ 2511.63 |
| 52 Week Low | $0.54 | $0.70 |
| 52 Week High | $1.64 | $2.59 |
Technical Indicators
Market Signals| Indicator | MDIA | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 47.55 |
| Support Level | $0.86 | $0.83 |
| Resistance Level | $0.93 | $1.51 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 18.59 | 57.67 |
Price Performance
Historical ComparisonAbout MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.